Has Ronald Jacobson received payments from drug or device companies?

Yes. Drug and device makers reported $3,788 in general payments to Ronald Jacobson across 118 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ronald Jacobson did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ronald Jacobson come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ronald Jacobson

Neurology with Special Qualifications in Child Neurology · Sleepy Hollow, NYNPI 1164519120

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,290 of the $3,788 with a category attached, or 60.5%. 29 manufacturers reported payments, led by Supernus Pharmaceuticals, Inc. at 35.1% of the total. Reporting peaked in 2019 at $1,946 and has fallen 93.6% since, to $124 in 2025.

$3,788in general payments, 2019–2025

Across 118 payments — averaging $32.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Supernus Pharmaceuticals, Inc.$1K
Sunovion Pharmaceuticals Inc.$237
Eisai Inc.$218
Ironshore Pharmaceuticals Inc.$184
Tris Pharma Inc$179
Eli Lilly$175
plus $1K from 23 others

What the payments were for

Consulting fees$1755%
Speaking & faculty fees$1,13530%
Travel & lodging$1805%
Food & beverage$2,29060%
Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Supernus Pharmaceuticals, Inc.	8	$1,330
Sunovion Pharmaceuticals Inc.	14	$237
Eisai Inc.	10	$218
Ironshore Pharmaceuticals Inc.	9	$184
Tris Pharma Inc	11	$179
Eli Lilly	1	$175
Greenwich Biosciences, Inc.	9	$170
Neuropace, Inc.	1	$162
Aquestive Therapeutics, Inc.	7	$135
Novartis Gene Therapies, Inc. (fka Avexis, Inc.)	1	$135
UCB, Inc.	1	$124
Novartis	4	$90
SK Life Science, Inc.	3	$85
Shire North American Group Inc	4	$74
CSL Behring	3	$70
Medtronic	4	$59
Neos Therapeutics, LP	3	$48
Takeda Pharmaceuticals U.S.A., Inc.	2	$45
Harmony Biosciences LLC	1	$36
Mallinckrodt Enterprises LLC	3	$34
AbbVie	1	$34
Corium, LLC	2	$33
Vertical Pharmaceuticals, LLC	2	$32
Adlon Therapeutics L.p.	2	$24
Mallinckrodt Hospital Products Inc.	1	$21
Sarepta Therapeutics, Inc.	1	$17
Catalyst Pharmaceuticals, Inc.	1	$17
Livanova USA, Inc.	1	$12
Travere Therapeutics, Inc.	8	$8

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,788 in reported general payments places this provider in the 80th percentile of 161 neurology with special qualifications in child neurology providers in New York.

See all neurology with special qualifications in child neurology providers in New York →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Vigabatrin	13	$105,740
TopamaxTopiramate	14	$36,154
Topiramate ErTopiramate	12	$19,536
VraylarCariprazine Hcl	11	$16,878
VyvanseLisdexamfetamine Dimesylate	25	$9,431
DepakoteDivalproex Sodium	13	$9,033
Tegretol XrCarbamazepine	12	$5,971
Gabapentin	22	$5,528
Divalproex Sodium	28	$3,896
Pimozide	12	$2,924
Oxcarbazepine	42	$2,864
Valproic AcidValproic Acid (As Sodium Salt)	22	$2,486
Levocarnitine	33	$2,054
Guanfacine Hcl	26	$1,578
Clobazam	21	$1,547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieVraylar	$34	$16,87811 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse	$45	$9,43125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 161 neurology with special qualifications in child neurology providers in New York.

Other neurology with special qualifications in child neurology in Sleepy Hollow

Claudia ChiribogaNew York$220K
Eric SegalN White Plains$133K
Kaleb YohayNew York$125K
Heather LauNew York$103K
Louis ManganasEast Setauket$86K
Darryl DevivoNew York$67K
Mary Lynn ChuNew York$66K
Jonathan MinkRochester$54K
Sanjeev KothareNew Hyde Park$53K
Mohammad QasaymehAmherst$42K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →